12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Talactoferrin: Phase III data

The double-blind, international Phase III FORTIS-M trial in 742 stage IIIb/IV NSCLC patients who have failed >=2 prior therapies showed that twice-daily 1.5 g oral talactoferrin plus best supportive care (BSC) missed the primary endpoint of median OS vs. placebo plus BSC (7.5 vs. 7.7 months, p=0.66). Agennix said the nature and incidence of adverse events between treatment arms were similar and consistent with previous trials. Based on the...

Read the full 322 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >